These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15017052)

  • 1. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
    Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
    Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
    Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.
    O'Neill B; Millington-Ward S; O'Reilly M; Tuohy G; Kiang AS; Kenna PF; Humphries P; Farrar GJ
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2863-9. PubMed ID: 10967039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An allele-specific hammerhead ribozyme gene therapy for a porcine model of autosomal dominant retinitis pigmentosa.
    Shaw LC; Skold A; Wong F; Petters R; Hauswirth WW; Lewin AS
    Mol Vis; 2001 Jan; 7():6-13. PubMed ID: 11172137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The application of ribozymes to HIV infection.
    Rossi JJ
    Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hammerhead ribozymes: biochemical and chemical considerations.
    Goodchild J
    Curr Opin Mol Ther; 2000 Jun; 2(3):272-81. PubMed ID: 11249621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic hammerhead ribozymes as therapeutic tools to control disease genes.
    Citti L; Rainaldi G
    Curr Gene Ther; 2005 Feb; 5(1):11-24. PubMed ID: 15638708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo RNA transcript-releasing plasmid possessing a universal pseudo-terminator by means of artificial ribozymes.
    Ohme-Takagi M; Shinshi H; Oda M; Uchimaru T; Nishikawa S; Taira K
    Nucleic Acids Symp Ser; 1990; (22):49-50. PubMed ID: 1714571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A computational approach to predict suitable target sites for trans-acting minimal hammerhead ribozymes.
    Mercatanti A; Lande C; Citti L
    Methods Mol Biol; 2012; 848():337-56. PubMed ID: 22315079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and production of asymmetric hammerhead ribozymes.
    Tabler M; Sczakiel G
    Methods Mol Biol; 1997; 74():141-9. PubMed ID: 9204429
    [No Abstract]   [Full Text] [Related]  

  • 14. Design of hybridizing arms in hammerhead ribozymes.
    Hendry P; McCall MJ; Lockett TJ
    Methods Mol Biol; 1997; 74():253-64. PubMed ID: 9204440
    [No Abstract]   [Full Text] [Related]  

  • 15. Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation.
    Pröpsting MJ; Blaschke M; Haas RE; Genschel J; Hedrich HJ; Manns MP; Schmidt HH
    Biochem Biophys Res Commun; 1999 Jul; 260(2):313-7. PubMed ID: 10403767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribozymes: structure, characteristics and use as potential antiviral agents.
    Bartolomé J; Madejón A; Carreño V
    J Hepatol; 1995; 22(1 Suppl):57-64. PubMed ID: 7602079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribozymes in the age of molecular therapeutics.
    Bagheri S; Kashani-Sabet M
    Curr Mol Med; 2004 Aug; 4(5):489-506. PubMed ID: 15267221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes.
    Nash KL; Alexander GJ; Lever AM
    J Viral Hepat; 2005 Jul; 12(4):346-56. PubMed ID: 15985004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and expression of chimeric U1/ribozyme transgenes.
    Abounader R; Montgomery R; Dietz H; Laterra J
    Methods Mol Biol; 2004; 252():209-19. PubMed ID: 15017051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimized hammerhead ribozymes.
    McCall MJ; Hendry P; Lockett TJ
    Methods Mol Biol; 1997; 74():151-9. PubMed ID: 9204430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.